Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
Pathology & Oncology Research
Literature
1.
Schwickart M, Huang X, Lill JR, Liu J, Ferrando R, French DM, Maecker H, O’Rourke K, Bazan F, Eastham-Anderson J, Yue P, Dornan D, Huang DC, Dixit VM (2010) Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature 463:103–107CrossRefPubMed
2.
Kushwaha D, O’Leary C, Cron KR, Deraska P, Zhu K, D’Andrea AD, Kozono D (2015) USP9X inhibition promotes radiation-induced apoptosis in non-small cell lung cancer cells expressing mid-to-high MCL1. Cancer Biol Ther 16:392–401CrossRefPubMedPubMedCentral
3.
Pérez-Mancera PA, Rust AG, van der Weyden L, Kristiansen G, Li A, Sarver AL, Silverstein KA, Grützmann R, Aust D, Rümmele P, Knösel T, Herd C, Stemple DL, Kettleborough R, Brosnan JA, Li A, Morgan R, Knight S, Yu J, Stegeman S, Collier LS, ten Hoeve JJ, de Ridder J, Klein AP, Goggins M, Hruban RH, Chang DK, Biankin AV, Grimmond SM, Initiative APCG, Wessels LF, Wood SA, Iacobuzio-Donahue CA, Pilarsky C, Largaespada DA, Adams DJ, Tuveson DA (2012) The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature 486:266–270PubMedPubMedCentral
4.
Oosterkamp HM, Hijmans EM, Brummelkamp TR, Canisius S, Wessels LF, Zwart W, Bernards R (2014) USP9X downregulation renders breast cancer cells resistant to tamoxifen. Cancer Res 74:3810–3820CrossRefPubMed
5.
Imai K, Yamamoto H (2008) Carcinogenesis and microsatellite instability: the interrelationship between genetics and epigenetics. Carcinogenesis 29:673–680CrossRefPubMed
6.
Yoo NJ, Kim HR, Kim YR, An CH, Lee SH (2012) Somatic mutations of the KEAP1 gene in common solid cancers. Histopathology 60:943–952CrossRefPubMed
7.
Murphy K, Zhang S, Geiger T, Hafez MJ, Bacher J, Berg KD, Eshleman JR (2006) Comparison of the microsatellite instability analysis system and the Bethesda panel for the determination of microsatellite instability in colorectal cancers. J Mol Diagn 8:305–311CrossRefPubMedPubMedCentral
8.
Oh HR, An CH, Yoo NJ, Lee SH (2015) Frameshift mutations of MUC15 gene in gastric and its regional heterogeneity in gastric and colorectal cancers. Pathol Oncol Res 21:713–718CrossRefPubMed
9.
Metadata
Title
USP9X, a Putative Tumor Suppressor Gene, Exhibits Frameshift Mutations in Colorectal Cancers
Authors
Yun Sol Jo
Min Sung Kim
Nam Jin Yoo
Sug Hyung Lee
Publication date
01-01-2017
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 1/2017
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-016-0140-z

Other articles of this Issue 1/2017

Pathology & Oncology Research 1/2017 Go to the issue

Original Article

Lipoprotein Lipase as a Prognostic Marker in Chronic Lymphocytic Leukemia

Original Article

Effects of Mesalazine on Morphological and Functional Changes in the Indomethacin-Induced Inflammatory Bowel Disease (Rat Model of Crohn’s Disease)

Original Article

Fucosyltransferase-4 and Oligosaccharide Lewis Y Antigen as potentially Correlative Biomarkers of Helicobacter pylori CagA Associated Gastric Cancer

Review

Diagnostic Biomarkers in Oral Verrucous Carcinoma: A Systematic Review

Original Article

Markers of Hippo-Pathway Activity in Tumor Forming Liver Lesions

Letter to the Editor

Genetic Screening in Pheochromocytoma/Paraganglioma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits